Covid Vaccine Race

The World Health Organization (WHO) listed the vaccine for emergency use to enable countries who do not have vaccine agreements in place to work towards vaccinating their populations.

Case numbers trend downward in Germany as UK implements new border policies.

New South Africa-based data show not only lessened protection versus the region's dominant variant, but a reduced vaccine-induced antibody neutralization.

Decision comes as Biden states all Americans won’t be vaccinated by the end of summer.

The country announced it is going to study the use of the Johnson & Johnson vaccine for health care workers and will not go forward with plans to use the AstraZeneca vaccine.

The UK announced it is beginning a 2-dose study using one dose of the Pfizer/BioNTech and one dose of AstraZeneca in each individual participant.

Our editor-in-chief rates the first year of response to the pandemic.

Iran reports 7,300 new cases as vaccination program is set to begin.

The two-dose vaccine's ineffective prevention of the more transmissible virus variant led to official seeking better options—and broader outcomes.

Pending advisory committee support and granted authorization, the adenovirus vaccine could become the first single-shot option in the US.

A protein subunit vaccine candidate for COVID-19 demonstrated safety and immunogenicity in a phase 1, placebo-controlled, dose escalation trial.

The company is reporting a reduced transmission after the first and second doses. However, questions are arising on the data around these claims and Switzerland declined to approve the vaccine.

New preliminary phase 3 data show the two-dose vaccine may even hold benefit for single-dose use.

The world is closing in on 100 million total vaccine doses administered.

Cohort data shows 87% of infants born to mothers with asymptomatic or symptomatic COVID-19 have developed antibodies at birth.

A video breakdown of the past week's developments and news in leading vaccine candidates.

The to-be-reviewed assessment of real-world vaccine recipients suggests 51% greater efficacy with BNT162b2 after 13-24 days.

The European Medicines Agency announced today it has recommended granting a commercial marketing authorization (CMA) to the company for its vaccine.

Data for its phase 3 trial shows differing levels of protection for moderate to severe disease depending on the geographic region.

The findings accompany news that the company is working on new vaccines to address more transmissible SARS-CoV-2 variants.

The US Centers for Disease Control and Prevention shares a similar outlook with the organization.

After setbacks to its own vaccine candidate, the major drug developer has agreed to aide in production for Europe-bound doses.

Using the Defense Production Act to aid in the effort remains on the table.

Roughly half the US population is now eligible to get a COVID-19 vaccine, according to health guidelines, but supply cannot keep up with demand.

On November 5, England went into a large scale lockdown to help curb the spread of the virus. This resurgence wasn’t unique to the UK though, but many have questioned the efficacy of such lockdowns, especially second ones.

Company announced it will continue developing 2 investigational therapeutics.

The United States and China make up nearly half of the globes vaccinations.

However, there is a six-fold reduction in neutralizing titers in the B.1.351 variant from South Africa, so the company is exploring strategies aimed against new variants.

Saliva testing for coronavirus disease 2019 (COVID-19) is as effective as the standard nasopharyngeal tests, according to a new study by investigators at McGill University.

With the news that the Pfizer and BioNtech COVID-19 vaccine vials can provide an extra dose, the federal agency updated the labeling so as to enable usage of low dead-volume syringes to extract it.